CellaVision AB (ST:CEVI) — Market Cap & Net Worth
Market Cap & Net Worth: CellaVision AB (CEVI)
CellaVision AB (ST:CEVI) has a market capitalization of $362.43 Million (Skr3.37 Billion) as of June 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #14028 globally and #221 in its home market, demonstrating a 11.89% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CellaVision AB's stock price Skr141.20 by its total outstanding shares 23851547 (23.85 Million). Review total liabilities of CellaVision AB to assess the company's total debt and financial obligations.
CellaVision AB Market Cap History: 2015 to 2026
CellaVision AB's market capitalization history from 2015 to 2026. Data shows growth from $164.81 Million to $362.43 Million (10.92% CAGR).
CellaVision AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CellaVision AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.53x
CellaVision AB's market cap is 0.53 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.64x
CellaVision AB's market cap is 2.64 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $209.01 Million | $265.04 Million | $59.80 Million | 0.79x | 3.50x |
| 2017 | $352.76 Million | $309.31 Million | $69.72 Million | 1.14x | 5.06x |
| 2018 | $474.47 Million | $364.81 Million | $88.69 Million | 1.30x | 5.35x |
| 2019 | $795.33 Million | $461.77 Million | $99.17 Million | 1.72x | 8.02x |
| 2020 | $764.21 Million | $471.44 Million | $89.48 Million | 1.62x | 8.54x |
| 2021 | $811.13 Million | $565.55 Million | $125.34 Million | 1.43x | 6.47x |
| 2022 | $574.90 Million | $639.34 Million | $118.33 Million | 0.90x | 4.86x |
| 2023 | $538.76 Million | $677.29 Million | $130.31 Million | 0.80x | 4.13x |
| 2024 | $558.28 Million | $723.22 Million | $140.72 Million | 0.77x | 3.97x |
| 2025 | $403.50 Million | $758.97 Million | $153.08 Million | 0.53x | 2.64x |
Competitor Companies of CEVI by Market Capitalization
Companies near CellaVision AB in the global market cap rankings as of June 19, 2026.
Key companies related to CellaVision AB by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #149 globally with a market cap of $153.89 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #212 globally with a market cap of $115.24 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #236 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #252 globally with a market cap of $100.32 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #149 | Abbott Laboratories | NYSE:ABT | $153.89 Billion | $88.50 |
| #212 | Stryker Corporation | NYSE:SYK | $115.24 Billion | $301.14 |
| #236 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #252 | Medtronic PLC | NYSE:MDT | $100.32 Billion | $78.14 |
CellaVision AB Historical Marketcap From 2015 to 2026
Between 2015 and today, CellaVision AB's market cap moved from $164.81 Million to $ 362.43 Million, with a yearly change of 10.92%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr362.43 Million | -10.18% |
| 2025 | Skr403.50 Million | -27.72% |
| 2024 | Skr558.28 Million | +3.62% |
| 2023 | Skr538.76 Million | -6.29% |
| 2022 | Skr574.90 Million | -29.12% |
| 2021 | Skr811.13 Million | +6.14% |
| 2020 | Skr764.21 Million | -3.91% |
| 2019 | Skr795.33 Million | +67.63% |
| 2018 | Skr474.47 Million | +34.50% |
| 2017 | Skr352.76 Million | +68.78% |
| 2016 | Skr209.01 Million | +26.82% |
| 2015 | Skr164.81 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of CellaVision AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $362.43 Million USD |
| MoneyControl | $362.43 Million USD |
| MarketWatch | $362.43 Million USD |
| marketcap.company | $362.43 Million USD |
| Reuters | $362.43 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CellaVision AB
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides digital hematology microscopy solutions, covering analyzers and instruments; and hardware products, including in vitro diagnostics IVD for laboratories; smear makers, stainers, stains, and staining protocols; DIFF-Line, a hematology la… Read more